Literature DB >> 19603527

Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis.

Jennelle C Hodge1, Peter J Park, Jonathan M Dreyfuss, Iman Assil-Kishawi, Priya Somasundaram, Luwam G Semere, Bradley J Quade, Allison M Lynch, Elizabeth A Stewart, Cynthia C Morton.   

Abstract

Uterine leiomyomata (UL), the most common neoplasm in reproductive-age women, have recurrent cytogenetic abnormalities including interstitial deletion of 7q. To develop a molecular signature, matched del(7q) and non-del(7q) tumors identified by FISH or karyotyping from 11 women were profiled with expression arrays. Our analysis using paired t tests demonstrates this matched design is critical to eliminate the confounding effects of genotype and environment that underlie patient variation. A gene list ordered by genome-wide significance showed enrichment for the 7q22 target region. Modification of the gene list by weighting each sample for percent of del(7q) cells to account for the mosaic nature of these tumors further enhanced the frequency of 7q22 genes. Pathway analysis revealed two of the 19 significant functional networks were associated with development and the most represented pathway was protein ubiquitination, which can influence tumor development by stabilizing oncoproteins and destabilizing tumor suppressor proteins. Array CGH (aCGH) studies determined the only consistent genomic imbalance was deletion of 9.5 megabases from 7q22-7q31.1. Combining the aCGH data with the del(7q) UL mosaicism-weighted expression analysis resulted in a list of genes that are commonly deleted and whose copy number is correlated with significantly decreased expression. These genes include the proliferation inhibitor HPB1, the loss of expression of which has been associated with invasive breast cancer, as well as the mitosis integrity-maintenance tumor suppressor RINT1. This study provides a molecular signature of the del(7q) UL subgroup and will serve as a platform for future studies of tumor pathogenesis. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19603527      PMCID: PMC2778251          DOI: 10.1002/gcc.20692

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  42 in total

1.  The frequency of uterine leiomyomas.

Authors:  S F Cramer; A Patel
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

2.  Cytogenetic abnormalities in uterine leiomyomata.

Authors:  M S Rein; A J Friedman; R L Barbieri; K Pavelka; J A Fletcher; C C Morton
Journal:  Obstet Gynecol       Date:  1991-06       Impact factor: 7.661

3.  Uterine leiomyomas: cytogenetic and histologic profile.

Authors:  A M Meloni; U Surti; A M Contento; J Davare; A A Sandberg
Journal:  Obstet Gynecol       Date:  1992-08       Impact factor: 7.661

Review 4.  Uterine leiomyomata: etiology, symptomatology, and management.

Authors:  V C Buttram; R C Reiter
Journal:  Fertil Steril       Date:  1981-10       Impact factor: 7.329

Review 5.  Uterine leiomyoma cytogenetics.

Authors:  M Nibert; S Heim
Journal:  Genes Chromosomes Cancer       Date:  1990-05       Impact factor: 5.006

6.  Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures.

Authors:  J Andersen; V M DyReyes; R L Barbieri; D M Coachman; R J Miksicek
Journal:  J Soc Gynecol Investig       Date:  1995 May-Jun

Review 7.  Deletion 7q22 in uterine leiomyoma. A cytogenetic review.

Authors:  Y Y Ozisik; A M Meloni; U Surti; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1993-11

Review 8.  The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.

Authors:  Angelika M Burger; Arun K Seth
Journal:  Eur J Cancer       Date:  2004-10       Impact factor: 9.162

9.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

10.  MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression.

Authors:  Lih-Wen Deng; Isaac Chiu; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

View more
  11 in total

1.  Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.

Authors:  Zehra Ordulu; Paola Dal Cin; Wilson W S Chong; Kwong Wai Choy; Charles Lee; Michael G Muto; Bradley J Quade; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

Review 2.  MLL5 (KMT2E): structure, function, and clinical relevance.

Authors:  Xiaoming Zhang; Wisna Novera; Yan Zhang; Lih-Wen Deng
Journal:  Cell Mol Life Sci       Date:  2017-02-10       Impact factor: 9.261

3.  Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12;14) and evidence in support of predisposing genetic heterogeneity.

Authors:  Jennelle C Hodge; Tae-Min Kim; Jonathan M Dreyfuss; Priya Somasundaram; Nicole C Christacos; Marissa Rousselle; Bradley J Quade; Peter J Park; Elizabeth A Stewart; Cynthia C Morton
Journal:  Hum Mol Genet       Date:  2012-02-17       Impact factor: 6.150

4.  miR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8.

Authors:  Tsai-Der Chuang; Xiaoping Luo; Harekrushna Panda; Nasser Chegini
Journal:  Mol Endocrinol       Date:  2012-05-03

Review 5.  Uterine leiomyomas: individualizing the approach to a heterogeneous condition.

Authors:  Shannon K Laughlin; Elizabeth A Stewart
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

Review 6.  Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma.

Authors:  Masanori Ono; Serdar E Bulun; Tetsuo Maruyama
Journal:  Biol Reprod       Date:  2014-11-05       Impact factor: 4.285

7.  No evidence for the role of somatic mutations and promoter hypermethylation of FH gene in the tumorigenesis of nonsyndromic uterine leiomyomas.

Authors:  Sireesha Vaidya; Noor Ahmad Shaik; Madhavi Latha; Srinivas Chava; Khaliq Mohiuddin; Annapurna Yalla; Kaipa Prabhakar Rao; Vijaya Lakshmi Kodati; Qurratulain Hasan
Journal:  Tumour Biol       Date:  2012-04-20

8.  An integrative genomic and transcriptomic analysis reveals potential targets associated with cell proliferation in uterine leiomyomas.

Authors:  Priscila Daniele Ramos Cirilo; Fábio Albuquerque Marchi; Mateus de Camargo Barros Filho; Rafael Malagoli Rocha; Maria Aparecida Custódio Domingues; Igor Jurisica; Anagloria Pontes; Silvia Regina Rogatto
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

9.  Role of stem cells in human uterine leiomyoma growth.

Authors:  Masanori Ono; Wenan Qiang; Vanida Ann Serna; Ping Yin; John S Coon; Antonia Navarro; Diana Monsivais; Toshiyuki Kakinuma; Matthew Dyson; Stacy Druschitz; Kenji Unno; Takeshi Kurita; Serdar E Bulun
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

Review 10.  Uterine Stem Cells and Benign Gynecological Disorders: Role in Pathobiology and Therapeutic Implications.

Authors:  Malak El Sabeh; Sadia Afrin; Bhuchitra Singh; Mariko Miyashita-Ishiwata; Mostafa Borahay
Journal:  Stem Cell Rev Rep       Date:  2020-11-05       Impact factor: 6.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.